Vobramitamab  (Synonyms: AEX-4089)

Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma^[1][2][3][4].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

B7-H3

MGC018 对所有 NB 细胞系 (IC₅₀ 范围 5.1-53.9 ng/mL) 和 NB MCTS (IC₅₀ 范围 17.8-364 ng/mL) 均具有剂量和时间依赖性的细胞毒性^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.691 kDa

2490556-50-6

液体

Colorless to light yellow

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Loaded Vobramitamab on AHC2 biosensor, can bind CD276/B7-H3 Protein, Mouse (HEK293, His，HY-P7639) with an affinity constant of 1.825E-09 M as determined in BLI assay.

• [1]. Brignole C, et al. Anti-tumor activity of vobramitamab duocarmazine (MGC018), an investigational duocarmycin-based anti-B7-H3 antibody-drug conjugate (ADC), in preclinical neuroblastoma models[J]. Cancer Research, 2023, 83(7_Supplement): 2981-2981.

  [2]. Brignole C, et al. Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma. J Immunother Cancer. 2023 Sep;11(9):e007174.  [Content Brief]

  [3]. Danielle C Kirkey MD, et al. CD276 (B7-H3) Is an Immunotherapeutic Target in Acute Myeloid Leukemia with Preclinical Efficacy of Vobramitamab Duocarmazine, an Investigational CD276 Antibody-Drug Conjugate. Blood.Volume 142, Supplement 1, 2 November 2023, Page 5958

  [4]. Scribner JA, et al. Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer. Mol Cancer Ther. 2020 Nov;19(11):2235-2244.  [Content Brief]